Less Is More for Rituximab in Low-Burden Follicular Lymphoma Medscape December 14, 2011 — For patients with low-tumor-burden follicular lymphoma, new data suggest that treatment with rituximab (Rituxan, Genentech) is better than a "watch-and-wait" strategy. In addition, outcomes with rituximab given only on disease ... ASH: Two Rituximab Dosing Strategies Come Out on Par |
